Skip to main content

Lluis Castells Fusté

Institutions of which they are part

Liver Diseases
Vall Hebron Institut de Recerca

Lluis Castells Fusté

Institutions of which they are part

Liver Diseases
Vall Hebron Institut de Recerca

Projects

Aplicación de la tecnología de secuenciación masiva para optimizar el coste-efectividad del tratamiento de la hepatitis C (VHC) en la era de los inhibidores de acción directa (DAAs).

IP: Juan Ignacio Esteban Mur
Collaborators: Lluís Viladomiu Catà, Lluis Castells Fusté, Josep Quer Sivila, Damir Garcia Cehic, Cristina Dopazo Taboada
Funding agency: Instituto de Salud Carlos III
Funding: 192692.5
Reference: PI13/00456
Duration: 01/01/2014 - 31/01/2017

Complejidad de la cuasiespecie del virus de la Hepatitis B en las regiones X, precore y core: Asociación con la severidad de la infección

IP: Francisco Rodríguez Frias
Collaborators: Clara Ramírez Serra, Lluis Castells Fusté, Silvia Camòs Anguila, Rafael Esteban Mur, David Tabernero Caellas
Funding agency: Instituto de Salud Carlos III
Funding: 98373
Reference: PI12/01893
Duration: 01/01/2013 - 31/03/2016

Expansión/restauración funcional de células CD4 NS3 específicas autólogas en la prevención de la recurrencia VHC post-trasplante hepático: optimización del proceso para uso clínico

IP: Juan Ignacio Esteban Mur
Collaborators: Itxarone Izaskun Bilbao Aguirre, Lluis Castells Fusté, Silvia Sauleda Oliveras, Isabel Campos Varela, Marta Bes Maijo, Maria Madeleine Piron
Funding agency: Instituto de Salud Carlos III
Funding: 135520
Reference: PI10/01505
Duration: 01/01/2011 - 30/06/2014

Estudio dinámico de quasispecies de VHC por pirosecuenciación en fase aguda y crónica durante tratamiento antiviral (PIROVIRUSC)

IP: Josep Quer Sivila
Collaborators: Itxarone Izaskun Bilbao Aguirre, Lluis Castells Fusté
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 121000
Reference: SAF2009-10403
Duration: 01/01/2010 - 31/12/2012

Ministerio de Ciencia

Related news

Preliminary study results confirm that the drug resmetirom reduces the presence of fat, inflammation, cell damage and fibrosis in the liver.

The European project, in which Vall d'Hebron participates, will favor personalized diagnosis and innovative therapeutic strategies in patients with the disease.

The research team used nanotechnology to deliver the drug directly to liver cells, which eliminated side effects without reducing effectiveness.

Related professionals

Olga Vallès Frutuoso

Olga Vallès Frutuoso

Research technician
Multidisciplinary Nursing Research Group
Read more
Helena Isla Magrané

Helena Isla Magrané

Research technician
Ophtalmology
Read more
Javier Garcia Fernandez

Javier Garcia Fernandez

Main researcher
Multidisciplinary Nursing Research Group
Read more
Marc  Díez  García

Marc Díez García

Research technician
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.